Dashboard
1
Poor Management Efficiency with a low ROE of 1.26%
- The company has been able to generate a Return on Equity (avg) of 1.26% signifying low profitability per unit of shareholders funds
2
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.18
3
Poor long term growth as Operating profit has grown by an annual rate -238.66% of over the last 5 years
4
Flat results in Dec 24
5
Risky -
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
25.88%
0%
25.88%
6 Months
57.35%
0%
57.35%
1 Year
94.55%
0%
94.55%
2 Years
386.36%
0%
386.36%
3 Years
-19.25%
0%
-19.25%
4 Years
-69.86%
0%
-69.86%
5 Years
-30.97%
0%
-30.97%
Allergy Therapeutics Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-6.40%
EBIT Growth (5y)
-238.66%
EBIT to Interest (avg)
-8.18
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.41
Sales to Capital Employed (avg)
1.66
Tax Ratio
0.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.95%
ROCE (avg)
5.14%
ROE (avg)
1.26%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-56.33
EV to EBIT
-13.94
EV to EBITDA
-16.16
EV to Capital Employed
41.64
EV to Sales
7.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-298.77%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bullish
Bullish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Jun 2018
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.95%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Jun'23
Jun'23
Jun'22
Change(%)
Net Sales
59.60
72.80
-18.13%
Operating Profit (PBDIT) excl Other Income
-30.60
-8.80
-247.73%
Interest
2.20
0.50
340.00%
Exceptional Items
-5.60
0.40
-1,500.00%
Consolidate Net Profit
-43.10
-13.80
-212.32%
Operating Profit Margin (Excl OI)
-584.90%
-178.70%
-40.62%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2023 is -18.13% vs -13.64% in Jun 2022
Consolidated Net Profit
YoY Growth in year ended Jun 2023 is -212.32% vs -575.86% in Jun 2022
About Allergy Therapeutics Plc 
Allergy Therapeutics Plc
Pharmaceuticals & Biotechnology
Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company's segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The Company provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company's products include Pollinex Trees, Pollinex Grasses+Rye, Skin Prick Testing and diagnostic products. Its vaccines trade under various brand names, such as Pollinex Quattro, Polligoid and TA Graser Top. It uses specialized systems to process the Tyrosine to form a suspension microcrystalline tyrosine (MCT) that is combined with some of its subcutaneous injected therapies.
Company Coordinates 
Company Details
Dominion Way , WORTHING None : BN14 8SA
Registrar Details






